a b s t r a c t
Venous thromboembolism (VTE) is a common cardiovascular disease, for which several single nucleotide polymorphisms (SNPs) underlying susceptibility were identified. Apart from candidate gene approach, genome-wide association studies (GWAS) have contributed to the identification of novel VTEassociated SNPs, including some with no clear role in the haemostatic system. These genetic variants constitute potential cancer-related biomarkers, particularly predictive and prognostic biomarkers, as a two-way association between VTE and cancer is well established. The present dataset comprises the data obtained from GWAS performed to identify genetic variants associated with VTE risk. Furthermore, this dataset also comprises data regarding previously reported candidate gene and validation reports performed in adults of European ancestry that also analysed the VTE GWASidentified variants. Lastly, to evaluate the impact of these genetic variants in carcinogenesis, a broad search was made, which has let us to establish putative links between several VTE-associated genes and cancer hallmarks in a review article entitled "Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: linkage to ovarian tumour behaviour". © 2020 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) The collection of VTE GWAS data (VTE variants' characterization, study population description and overall risk conferred by each variant in VTE GWAS) was made by screening the NHGRI-EBI GWAS catalogue . Regarding candidate gene and validation reports, data collection was performed by searching the NCBI database. As for the impact of VTE-associated genes in carcinogenesis, putative links with cancer hallmarks were established by searching the NCBI, GeneCards and Ensembl databases.
Specifications

Description of data collection
For VTE GWAS data collection, no restriction was made regarding the origin and age of the population. We gathered only the genetic variants statistically associated with VTE susceptibility in the GWAS´discovery phase ( P < 0.05). For candidate gene and validation reports, we only gathered the reports that analysed incident VTE among adults of European ancestry with no strong risk factors and performed before and after GWAS findings, respectively. In terms of the links between VTE-associated genes and cancer hallmarks, we gathered the information from reports that addressed this topic. 
Value of the data
• Given the existence of a tight and bilateral relationship between VTE and cancer, VTEassociated single nucleotide polymorphisms (SNPs) constitute potential cancer-related predictive and prognostic biomarkers that are currently in need. • Considering the growing incidence of VTE among cancer patients, with its underlying negative impact on patient prognosis, this dataset can benefit researchers and clinicians that work in the oncology field, who are interested in the genetic susceptibility for VTE, and how VTE-associated SNPs can be linked to cancer progression. • This database can be used for the development of several experiments as the majority of VTE genetic variants with a putative role in cancer progression have not been studied among cancer patients, particularly ovarian cancer patients who are frequently diagnosed with VTE and/or present a blood hypercoagulability state in the blood coagulation tests. Table 1 comprises the data obtained from GWAS performed to identify genetic variants that are associated with VTE susceptibility. Table 2 includes the data of a genome-wide search of pairwise SNP interactions associated with VTE risk. Table 3 encompasses data regarding previously reported candidate gene and validation reports of GWAS-identified SNPs that are associated with VTE risk. Table 4 includes putative links between VTE-associated genes and several cancer hallmarks.
Data
Experimental design, materials and methods
(1) GWAS addressing VTE susceptibility:
All SNPs statistically associated ( P < 0.05) with susceptibility to VTE (deep vein thrombosis, pulmonary embolism or both) were gathered by screening NHGRI-EBI GWAS catalogue and respective articles. No restriction was made regarding the origin and age of the population. In total, 12 VTE GWAS were collected, including ten in populations of European ancestry (one searching for pairwise SNP interactions associated with disease risk and one performed to determine the genetic factors of paediatric VTE) and two in Afro-American populations ( Fig. 1 ).
(2) Other reports reporting VTE-associated SNPs:
After gathering all GWAS-identified SNPs associated with VTE risk, data regarding validation and candidate gene reports that stated the same associations were also collected, using the NCBI database, in order to confirm the GWAS findings ( Fig. 1 ). Only SNPs reported by VTE GWAS among adults of European ancestry were considered. Hence, only validation and candidate gene reports with adults of European ancestry with incident VTE and with no strong risk factors were ( continued on next page ) 
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taken into account. To our best knowledge, the majority of VTE GWAS-reported SNPs are currently lacking validation.
(3) Putative links between VTE-associated genes and cancer hallmarks:
A vast search using NCBI, GeneCards and Ensembl databases ( Fig. 1 ) was made to collect data concerning VTE-associated genes and how they may be implicated in many cancer-related processes that contribute to cancer growth and progression.
